Qian X, Leonard F, Wenhao Y, Sudhoff H, Hoffmann T K, Ferrone S, Kaufmann A M, Albers A E
Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Department of Clinical Laboratory, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China.
HNO. 2020 Feb;68(2):94-99. doi: 10.1007/s00106-020-00819-y.
Cancer stem cell (CSC)-related therapy resistance has become a new obstacle to the successful application of cancer treatment and head and neck squamous cell carcinoma (HNSCC) is no exception to this finding. Head and neck squamous cell carcinoma is highly immune-suppressive, and recently the immune suppression and invasion of HNSCC-CSCs have been characterized. These characteristics have received research and clinical attention because they would enable the stratification of patients into specific cancer subtypes and, consequently, the establishment of new therapeutic approaches with improved efficacy. This review discusses the feasibility of CSC-targeted strategies and their incorporation with nanotechnology to improve the efficacy of cancer immunotherapy.
癌症干细胞（CSC）相关的治疗耐药性已成为癌症治疗成功应用的新障碍，头颈部鳞状细胞癌（HNSCC）也不例外。头颈部鳞状细胞癌具有高度免疫抑制性，最近HNSCC-CSCs的免疫抑制和侵袭特性已得到明确。这些特性受到了研究和临床关注，因为它们能够将患者分层为特定的癌症亚型，从而建立疗效更佳的新治疗方法。本文综述了靶向CSC策略的可行性及其与纳米技术的结合，以提高癌症免疫治疗的疗效。
